Malignant otitis externa

H8_EXT_MALIGN

No definition available.

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps	FinnGen
Phenotype data	519972
1. Apply sex-specific rule None	519972
2. Check conditions None	519972
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — H60.2 Hospital discharge: ICD-9 — 3801C Cause of death: ICD-10 — H60.2 Cause of death: ICD-9 — 3801C 2 out of 7 registries used, show all original rules.	67
4. Check minimum number of events None	67
5. Include endpoints None	67
6. Filter based on genotype QC (FinnGen only)	63

Control definitions (FinnGen only)

Control exclude: H8_EXTERNAL

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: H60
Name in latin: Otitis externa [maligna]

NAME	H8_EXT_MALIGN
CONTROL_EXCLUDE	H8_EXTERNAL
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	H602
HD_ICD_9	3801C
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	H602
COD_ICD_9	3801C
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Malignant otitis externa based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	540	251	283
Only index persons	480	228	252
Unadjusted period prevalence (%)
Whole population	0.01	0.01	0.01
Only index persons	0.01	0.01	0.01
Median age at first event (years)
Whole population	54.45	50.70	57.43
Only index persons	53.03	48.66	56.98

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	63	28	35
Unadjusted period prevalence (%)	0.01	0.01	0.02
Median age at first event (years)	57.48	47.51	65.44

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

Matched cohort

Matched cases
67: Matched controls
670

Code

Vocabulary

Description

Odds Ratio

-log₁₀(p)

N matched cases

N matched controls

H60.2

ICD-10 Finland

Malignant otitis externa

+∞

93.4

H60.9

ICD-10 Finland

Otitis externa, unspecified

22.3

19.4

H60.3

ICD-10 Finland

Other infective otitis externa

40.1

14.8

H60.8

ICD-10 Finland

Other otitis externa

68.7

14.5

H66.9

ICD-10 Finland

Otitis media, unspecified

12.0

8.9

H60

ICD-10 Finland

Otitis externa

13.4

8.8

H66.0

ICD-10 Finland

Acute suppurative otitis media

9.9

8.5

UDC00

NOMESCO Finland

Ear microscopy

9.5

8.3

Z01.1

ICD-10 Finland

Examination of ears and hearing

5.8

8.2

DC1AD

NOMESCO Finland

Temporalbone CT

89.6

7.6

H60.0

ICD-10 Finland

Abscess of external ear

+∞

7.4

H90.3

ICD-10 Finland

Sensorineural hearing loss, bilateral

4.6

7.0

J01MA02

ATC

ciprofloxacin; systemic

3.8

6.9

163

H70.1

ICD-10 Finland

Chronic mastoiditis

76.9

6.5

H72.0

ICD-10 Finland

Central perforation of tympanic membrane

29.8

6.4

215

Kela drug reimbursment

Diabetes, non-insulin-treated

3.8

6.3

LabWAS

↥

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3007853) Bacteria identified in Skin by Aerobe culture

9.67

18.32

3.7

1.9

—

(3000494) Fungus identified in Specimen by Culture

5.36

8.71

3.3

1.6

—

(3043924) Respiratory syncytial virus RNA [Identifier] in Specimen by NAA with probe detection

4.31

5.61

4.5

1.5

—

(3042936) Bacteria identified in Isolate by Culture

3.85

5.59

4.5

1.8

—

(3012516) Albumin [Mass/volume] in Urine

146

3.28

5.34

3.9

2.9

60.02

35.49

mg/l

0.29

(3020682) Albumin/Creatinine [Ratio] in Urine

154

3.25

5.30

4.7

3.2

16.66

4.10

mg/mmol

0.80

(3009508) Creatinine [Moles/volume] in Urine

159

3.12

4.95

3.8

2.7

6.95

8.15

mmol/l

0.87

138

(3006315) Basophils [#/volume] in Blood

242

3.17

4.90

9.2

6.0

0.05

0.04

e9/l

1.00

216

(36305247) Microscopic observation [Identifier] in Isolate by Gram stain

9.24

4.73

3.0

1.5

—

(40760892) CBC W Ordered Manual Differential panel - Blood

222

2.99

4.57

10.7

6.6

—

(3013115) Eosinophils [#/volume] in Blood

249

3.03

4.53

9.6

6.4

0.18

0.19

e9/l

0.24

225

(3019198) Lymphocytes [#/volume] in Blood

250

3.01

4.48

9.3

6.1

1.94

1.83

e9/l

0.33

228

(3001604) Monocytes [#/volume] in Blood

242

2.97

4.44

9.4

6.0

0.61

0.59

e9/l

0.21

215

(3038288) Influenza virus B RNA [Presence] in Specimen by NAA with probe detection

3.73

4.43

4.6

1.7

—

(3044938) Influenza virus A RNA [Presence] in Specimen by NAA with probe detection

3.33

4.39

4.4

1.9

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

7.66

3.45

1.7

1.5

—

(3027273) Bicarbonate [Moles/volume] in Venous blood

4.71

3.35

5.2

2.6

23.45

25.02

mmol/l

—

(3021337) Troponin I.cardiac [Mass/volume] in Serum or Plasma

2.81

3.35

10.2

2.9

440.92

188.96

ng/l

0.27

(3003458) Phosphate [Moles/volume] in Serum or Plasma

2.97

3.15

17.1

3.3

1.14

1.03

mmol/l

0.41

(3019060) Gas panel - Arterial blood

4.33

3.13

10.2

4.2

—

(3004410) Hemoglobin A1c/Hemoglobin.total in Blood

467

3.20

3.00

8.7

5.1

44.80

40.18

mmol/mol

1.58

439

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

4.35

2.89

24.0

6.0

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

5.44

2.81

1.7

1.4

—

(3020891) Body temperature

4.63

2.77

8.9

2.9

—

(3004119) Hemoglobin [Mass/volume] in Venous blood

3.83

2.59

5.0

2.3

117.56

132.58

g/l

—

(3009201) Thyrotropin [Units/volume] in Serum or Plasma

465

2.84

2.56

5.9

4.6

1.92

1.89

mu/l

0.08

424

(3022948) Iron [Moles/volume] in Serum or Plasma

2.60

2.39

7.1

1.8

11.07

16.18

umol/l

1.77

(3021614) Rheumatoid factor [Units/volume] in Serum or Plasma

2.47

2.38

1.2

12.04

13.43

iu/ml

—

(3021447) Carbon dioxide [Partial pressure] in Venous blood

3.01

2.34

6.2

2.2

5.80

5.71

kpa

0.15

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

3.18

2.32

2.5

1.7

—

(3021960) Folate [Moles/volume] in Serum or Plasma

114

2.23

2.19

1.8

1.5

15.16

20.08

nmol/l

0.84

(3023368) Bacteria identified in Blood by Culture

131

2.15

2.13

11.7

4.2

—

(3018251) Fasting glucose [Moles/volume] in Serum or Plasma

491

2.69

2.12

5.1

4.3

6.35

5.96

mmol/l

1.37

451

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

519

2.95

2.12

5.9

4.5

2.55

2.78

mmol/l

0.92

480

(3014162) Mycobacterium tuberculosis DNA [Presence] in Specimen by NAA with probe detection

3.78

2.12

4.7

2.8

—

(3021589) Normoblasts [#/volume] in Blood

208

2.03

2.09

22.0

9.3

0.00

e9/l

0.50

173

(3015377) Calcium [Moles/volume] in Serum or Plasma

157

2.07

4.0

3.7

2.31

2.36

mmol/l

0.73

138

(3000991) Gas panel - Venous blood

2.83

2.04

21.4

5.0

—

(43054903) Holo-transcobalamin II [Moles/volume] in Serum

177

2.00

1.95

2.7

1.9

86.62

88.87

pmol/l

0.11

(36031861) Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection

3.43

1.94

2.7

1.9

—

(3018418) pH of Serum or Plasma

138

2.02

1.83

15.6

3.8

7.41

7.40

—

(3024354) Oxygen [Partial pressure] in Venous blood

2.79

1.72

7.4

2.3

4.51

4.66

kpa

—

(3044889) 12 lead EKG panel

344

1.94

1.72

6.3

3.7

—

(3019800) Troponin T.cardiac [Mass/volume] in Serum or Plasma

202

1.88

1.69

4.7

3.8

58.55

25.50

ng/l

0.69

139

(40758558) Short blood count panel - Blood

126

1.97

1.66

7.4

7.6

—

(3024889) Methemoglobin/Hemoglobin.total in Venous blood

3.19

1.62

6.2

2.3

0.78

0.70

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

3.51

1.55

1.4

1.2

—

(3010517) Carboxyhemoglobin/Hemoglobin.total in Venous blood

3.03

1.54

6.3

2.4

1.28

1.12

—

(3016293) Bicarbonate [Moles/volume] in Serum or Plasma

3.03

1.54

28.7

6.0

24.68

23.65

mmol/l

—

(3031040) Bacteria [#/volume] in Urine by Automated count

331

1.83

1.53

7.5

4.1

—

24.29

—

(3014111) Lactate [Moles/volume] in Serum or Plasma

2.58

1.52

22.6

5.1

1.18

1.38

mmol/l

—

(3022217) INR in Platelet poor plasma by Coagulation assay

246

1.78

1.47

25.6

10.2

1.11

1.13

inr

—

(36660697) Celiac disease serology panel - Serum

2.33

1.42

1.1

—

(3000492) Spirometry study

2.32

1.40

1.1

1.6

—

(3017143) Hepatitis C virus Ab [Presence] in Serum

2.14

1.38

2.6

1.7

—

(3020460) C reactive protein [Mass/volume] in Serum or Plasma

516

2.20

1.36

37.7

13.6

25.39

23.80

mg/l

0.10

399

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

328

1.75

1.36

5.0

3.2

—

(40761511) CBC panel - Blood by Automated count

544

2.35

1.35

31.8

12.6

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

118

1.85

1.33

7.1

3.6

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

2.91

1.31

1.4

1.7

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

2.91

1.31

1.4

1.7

—

(3026008) Bacteria identified in Urine by Culture

136

1.79

1.29

5.0

2.8

—

(40768804) Tissue Pathology biopsy report

216

1.70

1.28

2.5

2.0

—

(3014576) Chloride [Moles/volume] in Serum or Plasma

2.03

1.23

22.2

5.9

104.25

104.00

mmol/l

0.07

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

483

1.97

1.22

4.5

3.6

1.64

1.28

mmol/l

2.07

448

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

1.92

1.20

2.5

1.7

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

1.83

1.16

2.3

1.8

—

(3014007) Fractional oxyhemoglobin in Arterial blood

2.48

1.16

27.6

6.5

92.19

94.82

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

107

1.79

1.13

2.9

2.3

—

(3006217) Methemoglobin/Hemoglobin.total in Arterial blood

2.32

1.12

27.4

6.2

0.66

0.73

—

(3028653) Carboxyhemoglobin/Hemoglobin.total in Arterial blood

2.32

1.12

27.4

6.2

1.84

1.55

—

(3014218) Bicarbonate [Moles/volume] standard in Arterial blood

2.49

1.11

32.6

7.0

23.60

23.69

mmol/l

—

(3004789) Transferrin [Mass/volume] in Serum or Plasma

2.00

1.10

9.5

1.7

2.19

2.49

g/l

0.80

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

100

1.79

1.09

2.1

1.6

0.38

1.26

mg/l

—

(3024561) Albumin [Mass/volume] in Serum or Plasma

206

1.62

1.06

11.5

4.1

33.83

35.86

g/l

1.38

200

(586526) SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection

2.18

1.06

1.6

1.4

—

(3023520) Reticulocytes [#/volume] in Blood

2.11

1.03

1.7

69.80

74.30

e9/l

—

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

505

1.86

0.99

5.1

4.0

1.32

1.47

mmol/l

1.64

469

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

505

1.86

0.99

5.3

4.1

4.47

4.66

mmol/l

0.57

471

(3007164) IgA [Mass/volume] in Serum or Plasma

112

1.69

0.97

1.5

1.4

2.37

2.17

g/l

—

(40764999) Glomerular filtration rate/1.73 sq M.predicted [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)

484

1.76

0.95

25.4

12.4

79.40

84.99

ml/min/173m2

0.72

404

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

230

1.55

0.94

4.5

2.3

—

(3037467) Urinalysis macro (dipstick) panel - Urine

349

1.55

0.90

6.2

3.8

—

(3033658) Prothrombin time (PT) actual/Normal

123

1.63

0.90

8.3

3.5

95.22

92.63

0.20

123

(3020564) Creatinine [Moles/volume] in Serum or Plasma

549

1.89

0.89

35.9

15.8

95.72

74.82

umol/l

1.11

549

(3044640) Blood type and Crossmatch panel - Blood

150

1.58

0.88

3.4

2.3

—

(40761535) Cells panel - Urine sediment

1.84

0.86

4.9

3.6

—

(4035726) Immunohistochemistry procedure

1.84

0.86

1.1

1.3

—

(3002256) Pathology report gross observation

1.82

0.81

1.1

1.2

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.81

0.0

1.7

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

2.17

0.76

4.0

2.1

—

(3019902) Methicillin resistant Staphylococcus aureus [Presence] in Specimen by Organism specific culture

1.79

0.72

13.0

3.3

—

(3004588) Protein electrophoresis panel - Serum or Plasma

1.85

0.67

1.2

2.2

—

(4200892) Spirometry reversibility

1.66

0.67

1.6

—

(3029879) Epithelial cells.squamous [#/volume] in Urine by Automated count

1.63

0.64

6.5

2.8

1.33

3.04

e6/l

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

179

1.43

0.63

6.2

2.9

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.61

0.0

1.5

—

(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma

172

1.42

0.58

5.4

3.3

36.59

29.39

u/l

0.39

163

(3021879) Hepatitis B virus core Ab [Presence] in Serum

1.73

0.58

1.5

1.9

—

(3024135) Streptococcus.beta-hemolytic [Presence] in Throat by Organism specific culture

100

0.56

0.57

1.5

1.4

—

(3045783) Sodium and Potassium panel [Moles/volume] - Serum or Plasma

1.47

0.54

8.4

8.1

—

(40768797) Stomach Pathology biopsy report

1.58

0.53

1.8

1.3

—

(3009035) Cobalamin (Vitamin B12) [Moles/volume] in Serum or Plasma

104

1.44

0.48

1.5

1.7

504.29

489.16

pmol/l

0.05

(3003338) MCHC [Mass/volume]

435

1.36

0.48

45.1

18.0

333.06

332.92

g/l

0.04

435

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

1.49

0.45

2.1

1.8

—

(3041942) Cyclic citrullinated peptide Ab [Units/volume] in Serum

1.47

0.44

1.4

1.3

1.00

11.78

u/ml

—

(3010521) Mycoplasma pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.42

0.0

1.1

—

(3000570) Elastase.pancreatic [Mass/mass] in Stool

0.00

0.41

0.0

1.6

—

251.03

—

(3014051) Protein [Presence] in Urine by Test strip

0.00

0.41

0.0

1.7

—

(3009261) Glucose [Presence] in Urine by Test strip

259

1.29

0.40

6.3

3.4

0.00

estimate

—

(3035350) Ketones [Presence] in Urine by Test strip

260

1.28

0.39

6.3

3.3

0.00

estimate

—

(36304419) Bacteria [Presence] in Urine

146

1.32

0.37

6.9

2.6

—

(40761536) Microorganisms panel - Urine sediment

1.43

0.36

4.8

2.7

—

(3021601) Nitrite [Presence] in Urine by Test strip

254

1.25

0.33

8.6

4.3

0.00

estimate

—

(1761868) Lipid panel - Serum or Plasma

192

0.78

0.31

3.3

2.7

—

(3003694) ABO and Rh group [Type] in Blood

142

1.26

0.28

1.4

1.5

—

(3019225) pH of Specimen

1.34

0.24

1.8

5.6

—

(3041096) Erythrocytes [Presence] in Urine by Automated

155

0.80

0.23

3.8

2.6

—

(3006588) Cancer Ag 15-3 [Units/volume] in Serum or Plasma

0.00

0.21

0.0

3.5

—

17.09

—

(21493466) Plesiomonas shigelloides DNA [Presence] in Stool by NAA with non-probe detection

0.00

0.21

0.0

2.1

—

(3005988) Vibrio sp identified in Specimen by Organism specific culture

0.00

0.21

0.0

2.1

—

(3047007) Chlamydophila sp Ab [Presence] in Serum

0.00

0.21

0.0

1.2

—

(3027545) Mycoplasma pneumoniae Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.4

—

(44816559) Phosphatidylethanol [Mass/volume] in Blood

0.00

0.21

0.0

1.2

—

(1175715) Chlamydophila pneumoniae IgM Ab [Presence] in Serum by Immunoassay

0.00

0.21

0.0

1.2

—

(40768793) Breast Pathology biopsy report

0.00

0.21

0.0

1.2

—

(1002102) Choriogonadotropin.intact+Beta subunit [Mass/volume] in Serum or Plasma

0.00

0.21

0.0

1.5

—

(21492888) Glucose tolerance 2 hours gestational panel - Serum or Plasma

0.00

0.20

0.0

1.7

—

(3020321) Streptococcus agalactiae [Presence] in Vaginal fluid by Organism specific culture

0.00

0.20

0.0

1.8

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

150

1.18

0.16

5.0

4.7

18.82

20.59

—

(3013512) EKG study

132

1.18

0.15

5.0

3.4

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

210

1.15

0.14

6.3

3.4

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

1.06

0.09

2.0

1.9

—

(3022145) Colonoscopy Study observation

0.82

0.08

1.4

1.3

—

(3018006) Microscopic observation [Identifier] in Cervix by Cyto stain.thin prep

1.05

0.07

1.6

1.5

—

(3028707) Methadone [Presence] in Urine by Screen method

0.00

0.0

2.0

—

(3048821) Cortisol [Moles/volume] in Serum or Plasma --post 1 mg dexamethasone PO overnight

0.00

0.0

1.3

—

(3018387) Mycoplasma pneumoniae IgG Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.0

—

(3025468) Yersinia sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

2.2

—

(37020445) Astrovirus RNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

2.0

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

0.00

-0.00

0.0

1.8

—

(3024522) Salmonella sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

2.2

—

(3049539) Genetic diseases [Identifier] in Blood or Tissue by FISH Nominal

0.00

-0.00

0.0

1.0

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

-0.00

0.0

1.0

—

(3032773) Endomysium IgG Ab [Titer] in Serum

0.00

-0.00

0.0

1.0

—

(3028531) Enolase.neuron specific [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.8

—

13.69

—

(3014973) Borrelia burgdorferi IgM Ab [Units/volume] in Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

(3045142) Bone marrow Pathology biopsy report

0.00

-0.00

0.0

1.6

—

(37021247) Adenovirus 40+41 DNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

2.0

—

(40768795) Lymph node Pathology biopsy report

0.00

-0.00

0.0

1.1

—

(3010380) Borrelia burgdorferi IgG Ab [Units/volume] in Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

(3019832) Treponema pallidum Ab [Presence] in Serum

0.92

-0.00

1.8

1.7

—

(3020491) Glucose [Moles/volume] in Blood

0.00

-0.00

0.0

3.0

—

6.34

—

(3014791) Apolipoprotein B [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.6

—

1.02

—

(3012568) Campylobacter sp identified in Specimen by Organism specific culture

0.00

-0.00

0.0

2.2

—

(3004915) Chlamydophila pneumoniae IgA Ab [Units/volume] in Serum

0.00

-0.00

0.0

1.1

—

(3011166) Borrelia burgdorferi Ab [Presence] in Cerebral spinal fluid

0.00

-0.00

0.0

1.0

—

(3008364) Apolipoprotein A-I [Mass/volume] in Serum or Plasma

0.00

-0.00

0.0

1.6

—

1.71

—

(3024666) Lithium [Moles/volume] in Serum or Plasma

0.00

-0.00

0.0

10.8

—

0.60

—

(36305771) Cryptosporidium sp DNA [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

1.2

—

(42868716) Shigella species+EIEC invasion plasmid antigen H ipaH gene [Presence] in Stool by NAA with probe detection

0.00

-0.00

0.0

2.2

—

(3035637) Corticotropin [Mass/volume] in Plasma

0.00

-0.00

0.0

1.8

—

(3043405) Microscopic observation [Identifier] in Specimen by Non-gynecological cytology method

0.00

-0.00

0.0

1.6

—

(3023410) Appearance of Cerebral spinal fluid

0.00

-0.00

0.0

1.3

—

(42529200) Cancer Ag 15-3 [Units/volume] in Serum or Plasma by Immunoassay

0.00

-0.00

0.0

7.7

—

182.62

—

(3015024) Glucose [Moles/volume] in Serum or Plasma --1 hour post dose glucose

0.00

-0.00

0.0

1.3

—

6.72

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

0.00

-0.00

0.0

1.1

—

(3004616) Nuclear Ab [Presence] in Serum

0.00

-0.00

0.0

1.0

—

(3016417) Amylase.pancreatic [Enzymatic activity/volume] in Serum or Plasma

0.92

-0.00

3.2

2.8

56.00

27.64

u/l

—

(3013327) Hepatitis A virus IgM Ab [Presence] in Serum

0.00

-0.00

0.0

1.0

—

Mortality – FinRegistry

↥

Association

Association between endpoint H8_EXT_MALIGN and mortality.

Females

No data

Males

Parameter	HR [95% CI]	p-value
H8_EXT_MALIGN	1.384 [0.95, 2.01]	0.086
Birth year	0.989 [0.98, 1.0]	0.022

During the follow-up period (1.1.1998 — 31.12.2019), 73 out of 238 males with H8_EXT_MALIGN died.

Mortality risk

Mortality risk for people of age

years, who have H8_EXT_MALIGN.

N-year risk	Females	Males
1	No data	0.279%
5	No data	1.591%
10	No data	4.158%
15	No data	8.048%
20	No data	13.472%

Relationships between endpoints

↥

Index endpoint: H8_EXT_MALIGN – Malignant otitis externa

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Malignant otitis externa

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS

Matched cohort

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints